These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20806121)

  • 1. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
    Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
    Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
    Hu L; Fan Z; Du H; Ni R; Zhang S; Yin K; Ye J; Zhang Y; Wei X; Zhang X; Gross PL; Kunapuli SP; Ding Z
    Thromb Haemost; 2011 Dec; 106(6):1203-14. PubMed ID: 21946947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets.
    Fälker K; Lange D; Presek P
    Thromb Haemost; 2005 May; 93(5):880-8. PubMed ID: 15886804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
    Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
    Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
    Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats.
    Sugidachi A; Yamaguchi S; Jakubowski JA; Ohno K; Tomizawa A; Hashimoto M; Niitsu Y
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):329-34. PubMed ID: 21697729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
    Storey RF; Wilcox RG; Heptinstall S
    Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism of P2Y₁₂ reduces physiological thromboxane levels.
    Bhavaraju K; Georgakis A; Jin J; Gartner TK; Tomiyama Y; Nurden A; Nurden P; Kunapuli SP
    Platelets; 2010; 21(8):604-9. PubMed ID: 21067313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
    Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
    Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.
    Bryant J; Post JM; Alexander S; Wang YX; Kent L; Schirm S; Tseng JL; Subramanyam B; Buckman B; Islam I; Yuan S; Sullivan ME; Snider M; Morser J
    Thromb Res; 2008; 122(4):523-32. PubMed ID: 18495218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
    Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
    Platelets; 2006 Aug; 17(5):318-27. PubMed ID: 16928604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelets Express Activated P2Y
    Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
    Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.